Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | NMT1 | P30419 | 4/20 | 0.38 |
| ▸ | NMT2 | O60551 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20800932 | 0.84 | GLP1R (0.43) | GLP1RGRIN1GRIN2ACHRNB2CHRNB4 | |
| SCHEMBL18715404 | 0.83 | GLP1R (0.43) | GLP1RGRIN1GRIN2ACHRNB2CHRNB4 | |
| SCHEMBL24479569 | 0.83 | GLP1R (0.43) | GLP1RGRIN1GRIN2ACHRNB2CHRNB4 | |
| SCHEMBL23551036 | 0.83 | GLP1R (0.43) | GLP1RGRIN1GRIN2ACHRNB2CHRNB4 | |
| SCHEMBL18715377 | 0.83 | GLP1R (0.43) | GLP1RGRIN1GRIN2ACHRNB2CHRNB4 | |
| SCHEMBL24479396 | 0.83 | GLP1R (0.42) | GLP1RGRIN1GRIN2ACHRNB2CHRNB4 | |
| SCHEMBL21287423 | 0.83 | GLP1R (0.42) | GLP1RGRIN1GRIN2ACHRNB2CHRNB4 | |
| SCHEMBL20375331 | 0.83 | GLP1R (0.42) | GLP1RGRIN1GRIN2ACHRNB2CHRNB4 | |
| SCHEMBL24264671 | 0.82 | GLP1R (0.43) | GLP1RGRIN1GRIN2A | |
| SCHEMBL20375531 | 0.82 | GLP1R (0.43) | GLP1RGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257749-A1 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257749-A1 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFB, CFH, RNASE1 | GLP1R 4438/4885GRIN1 4626/4885GRIN2A 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.